Company
RespireRx Pharmaceuticals
OTCMKTS:RSPI
RespireRx Pharmaceuticals Inc is a biopharmaceutical company developing innovative and revolutionary treatments to combat disorders caused by disruption of neuronal signaling. It is developing treatment options that address conditions that affect millions of people, but for which there are limited or poor treatment options, including obstructive sleep apnea (OSA), attention deficit hyperactivity disorder (ADHD) epilepsy, chronic pain, spinal cord injury (SCI).
24 stories
RespireRx Pharmaceuticals signs letter of intent with Australian CRO to study drug for treating obstructive sleep apnea
RespireRx aims to establish an Australian subsidiary, possibly to be named ResolutionRx to do research and development
RespireRx Pharmaceuticals says its obstructive sleep apnea drug dronabinol featured in Sleep Review magazine free e-book
The e-book, entitled 'How Close Are We to Drug Therapy for Obstructive Sleep Apnea?' discusses dronabinol as one of four emerging drug treatments for the treatment of OSA
RespireRx Pharmaceuticals Interim CEO talks AMPAkines in treating GRI disorders at virtual conference
Lippa described the work that EndeavourRx, the company’s business unit focused on neuromodulators, has done to develop a novel class of low-impact AMPAkines that have shown positive results in human studies of target engagement
RespireRx Pharmaceuticals highlights experimental data suggesting its GABAkine KRM-II-81 could be game-changing for tinnitus patients
First author of the article Jeffrey Witkin said the experimental data on GABA suggested the possibility that GABAkines such as RespireRx’s KRM-II-81 could be game-changing for tinnitus patients
RespireRx Pharmaceuticals files provisional patent application for lipid-based formulation technology to develop cannabinoids
ResolutionRx, the company’s business unit focused on pharmaceutical cannabinoids, has been developing dronabinol, a synthetic form of THC
RespireRx Pharmaceuticals notes publication of paper on newest GABAkine analog which protects against seizures and lethality
This latest asset is a structurally related analog to KRM-II-81, which, as previously reported, RespireRX's EndeavourRx business unit is advancing for the treatment of epilepsy and chronic pain
RespireRx Pharmaceuticals CEO announces internal restructuring, plans further clinical trials in 2022
The company has implemented an internal restructuring plan through which its two-drug platforms have been reorganized into separate business units and may in the future be organized into private subsidiaries of RespireRx
RespireRx Pharmaceuticals notes publication of paper on GABAkine KRM-II-81, which it is advancing for epilepsy and pain
RespireRx is advancing a portfolio of innovative drugs to combat neurological and psychiatric conditions and its EndeavourRx business unit is advancing KRM-II-81 to treat epilespy and chronic pain
RespireRx Pharmaceuticals is advancing an innovative portfolio targeting poorly or unmet patient need
With a market cap of US$1.7 million, the company aims to develop treatments, based on modifying neurotransmission (brain signalling), which have advantages to currently available drugs, if there are any